

1 **SARS-CoV-2 Seroprevalence and Risk Factors among Convalescents in Sichuan Province,**  
2 **China: a retrospective cohort study**

3 Lijun Zhou<sup>1\*</sup>, Cheng Li<sup>2\*</sup>, Huiping Yang<sup>1\*</sup>, Heng Yuan<sup>1</sup>, Ming Pan<sup>1</sup>, Xiuwei Cheng<sup>1</sup>,  
4 Chongkun Xiao<sup>1</sup>, Xiaoyan Su<sup>3</sup>, Yuanfang Zhu<sup>4</sup>, Jianan Xu<sup>1</sup>, Jianxiang Tang<sup>2</sup>, Xunbo Du<sup>5</sup>,  
5 Huanwen Peng<sup>6</sup>, Chen Xiao<sup>7</sup>, Tao Huang<sup>8</sup>, Hongxiu Liao<sup>9</sup>, Deqiang Xian<sup>9</sup>, Hongxiu Liao<sup>10</sup>,  
6 HaoZhou Wang<sup>11</sup>, Wenwu Liu<sup>12</sup>, Zhou Ping<sup>13</sup>, Zhengdong Zhang<sup>14</sup>, Liu Juan<sup>15</sup>, Xianping Wu<sup>1#</sup>,  
7 Tao Zhang<sup>2#</sup>

8  
9 1 Center for Disease Control and Prevention of Sichuan, Chengdu, Sichuan 610041, China

10 2 Department of Epidemiology and Health Statistics, West China School of Public Health and  
11 West China Fourth Hospital, Sichuan University, Sichuan 610041, China

12 3 Center for Disease Control and Prevention of Lu County, Luzhou, Sichuan 646100, China

13 4 Center For Disease Control And Prevention of Gulin county, Luzhou, Sichuan 646500, China

14 5 Center for Disease Control and Prevention of Chengdu, Chengdu, Sichuan 610041, China.

15 6 Center for Disease Control and Prevention of Dazhou, Dazhou, Sichuan 635002, China

16 7 Center for Disease Control and Prevention of Nanchong, Nanchong, Sichuan 637000, China

17 8 Center for Disease Control and Prevention of Guangan, Guangan, Sichuan 638000, China

18 9 Center for Disease Control and Prevention of Luzhou, Luzhou, Sichuan 646000, China

19 10 Center for Disease Control and Prevention of Panzhihua, Panzhihua 617000, Sichuan, China

20 11 Center for Disease Control and Prevention of MianYang, MianYang, Sichuan 621050, China

21 12 Center for Disease Control and Prevention of Suining, suining, Sichuan 629000, China

22 13 Center for Disease Control and Prevention of Yibin, Yibin, Sichuan 644000, China

23 14 Center for Disease Control and Prevention of Zigong, Zigong, Sichuan 643000, China

24 15 Center for Disease Control and Prevention of NeiJiang ,NeiJiang Sichuan 641000, China

25

26 \*Lijun Zhou, Cheng Li and Huiping Yang contributed equally to this manuscript

27 #Xianping Wu and Tao Zhang contributed equally to this manuscript

28

29 **Correspondence:** Tao Zhang, Department of Epidemiology and Health Statistics, West China

30 School of Public Health and West China Fourth Hospital, Sichuan University, Renmin South

31 Road 3rd Section NO.16 , Chengdu 610041, Sichuan, E-mail: scdxzhangtao@163.com, Tel

32 number: +8615908141271

33

## 34 **Abstract**

35 **Objectives:** To understand SARS-CoV-2 seroprevalence of convalescents and assess their the  
36 immunity. Furthermore, we intend to explore the association between antibody levels and with  
37 demographic factors.

38 **Methods:** 177 COVID-19 convalescents in Sichuan Province were voluntarily participated in our  
39 study. 363 serum samples were collected from June, 2020 to November, 2020. Duration of  
40 seroprevalence in these convalescents and their demographic characteristics were described, and  
41 the risk factors to antibody levels were analysed.

42 **Results:** Men had more than twice the odds of having IgM antibody positive compared with  
43 women (OR=2.419, 95% CI:[1.232, 4.751]). Participants without symptoms were nearly 0.5  
44 times IgG seropositive than those with symptoms (OR=0.455, 95% CI: [0.220, 0.940]). People  
45 aged $\geq$ 60 years were nearly 3 times IgG seropositive than those who aged < 20 years (OR=2.986,  
46 95% CI: [1.058, 8.432]). Seroprevalence in asymptomatic declined quicker than symptomatic.

47 **Conclusions:** Age and gender may affect the antibody levels and seroprevalence. Asymptomatic  
48 appeared more easier to turn to seronegative than symptomatic.

49 **Keywords:** Seroprevalence; SARS-CoV-2; Risk Factors

## 50 **Introduction**

51 The global pandemic of coronavirus disease 2019(COVID-19), an emerging infectious  
52 disease resulted from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has pose  
53 enormous threat to public health[1]. The epidemiological and serological characteristics of  
54 patients with COVID-19, have been explicitly reported[2], but the seroprevalence, serological  
55 characteristics and immunity of convalescents remain largely obscure.

56           Antibody response is crucial to eliminate viral infection[3], and the seroprevalence of  
57 specific serum antibodies immunoglobulin M (IgM) and immunoglobulin G(IgG) against SARS-  
58 CoV-2 can provide immune protection. Understanding seroprevalence dynamic of SARS-CoV-2  
59 assists to assess the immune levels of convalescents, and it also helps to predict the potential  
60 protection in the future [4]. As the number of patients recovering from the SARS-CoV-2  
61 continues to increase, the duration of individual serological responses has also sparked public  
62 attention[5]. It is important to know whether and how demographic factors (such as age, gender,  
63 origin and type) affect serological responses during SARS-CoV-2 infection. In several countries,  
64 initial case reports have symptomatic to be re-infected with SARS-CoV-2 [6]. There is an urgent  
65 need to understand how long the antibody response to the virus will last after infection. For one  
66 thing, monitoring specific antibodies can benefit to distinguish vaccine-related antibodies from  
67 infected-stimulated ones[7]. For another, the study of serological dynamic also help to  
68 understand the associated serological epidemiology.

69           IgM is the first immune response against viral infection, and IgG production lags behind  
70 IgM but provides long-term immunity[8], similar to coronavirus infections such as SARS and  
71 MERS[9]. Usually IgM antibodies last less time in the body, and previous studies in SARS  
72 patients have shown that specific IgM antibodies last for 13 weeks in the body[10], as well as  
73 IgG antibodies are longstanding with an average of about 2 years[11]. The decline of IgM is seen  
74 as a indicator of virus clearance and convalescents could have robust immunity against re-  
75 infection with positive antibody, the reduction of IgG prompt serious concerns on the robustness  
76 and persistence of immunity after recovering[12], which is primary for developing vaccine and  
77 making immunity strategy. Studying the risk factors and dynamic change of different antibodies  
78 can help to understand the body's resistance to SARS-CoV-2 at different stages. At the same

79 time, information regarding the persistence of immunity to SARS-CoV-2 infection facilitate the  
80 continued development of new vaccines and clinical therapeutics[13]. In our study, the  
81 serological level of 177 convalescents of SARS-CoV-2 in Sichuan Province were reviewed and  
82 analyzed. At present, the literature reported that the seroprevalence of specific IgM antibodies  
83 and IgG antibodies persisted to 8 months[14], but the positive antibody duration still needs to  
84 update.

85 However, most of previous researches have mainly spotlighted on the acute response  
86 within several weeks after clinical onset in SARS-CoV-2. While the number of convalescents  
87 infected with SARS-CoV-2 started to escalate, evaluating and understanding the immune  
88 response becomes even more essential. This study intends to assess whether seroprevalence is  
89 associated with demographic factors, such as gender, age, type (symptomatic cases or  
90 asymptomatic cases) and travel history(domestic or international). Meanwhile, we aims to  
91 describe the serum dynamic changes and durability of convalescents of SARS-CoV-2.. It is  
92 expected that serological study of SARS-Cov-2 convalescents during the recovery period will  
93 benefit to understand the immunological response to SARS-CoV-2 infection. Moreover, It also  
94 provides an auxiliary scientific basis for clinical development and evaluation of SARS-CoV-2  
95 vaccine.

## 96 **Methods**

### 97 *Study design*

98 This study is a retrospective cohort study that included 177 convalescents in Sichuan  
99 Province as of November 23, 2020. All subjects voluntarily joined serological researches with  
100 informed consent. 363 serum samples and demographic characteristics of 177 convalescents  
101 were collected.

102 ***Data and specimen collection***

103           The data was collected by the Centers for Disease Control and Prevention in Sichuan  
104 Province, and consisted of the demographic characteristics of the 177 convalescents and their  
105 longitudinal antibody results (363 serum samples) till November 23, 2020. Specimens were  
106 collected from June 23, 2020 on the basis of voluntary informed consent of COVID-19  
107 convalescents. Volunteers can withdraw from the study at any time in accordance with the  
108 principle of informed consent. All 363 serum samples were detected by the Institute of  
109 Microbiology and Analysis.

110 ***Detection of IgG and IgM***

111           Non-anticoagulant specimens (intravenous blood collection) were collected for all  
112 subjects, 3mL for children (<5 years) , and 5mL for others. Serum samples were collected and  
113 loaded into sealed bags in accordance with Class A transport packaging, refrigerated and  
114 transported to the local CDC laboratory for serum separation. The isolated serum was stored in a  
115 1.5 mL freeze deposit tube at -20 degrees C. The Mike i1000 fully automated luminescent  
116 immunoanalyzer (base fluid lot number: 0520153; reagent lot number: 0520031,0520032;  
117 reaction cup lot number: 0720582;) was utilized to test serum by the principle of direct chemical  
118 luminescence immunoanalysis.

119 ***Ethical approval***

120           The survey was discussed with the Ethics Committee of Center for Disease Control  
121 and Prevention in Sichuan Province, who reviewed the content. And the ethical approval was  
122 given. All participants assented informed consent before participation, and this study was  
123 conducted in accordance with Good Clinical Practice(GCP). This study was performed in  
124 compliance with all relevant ethical regulations and the protocol for human subject studies was

125 approved by the Center for Disease Control and Prevention in Sichuan Province(SCCDCIRB-  
126 2020-007).

### 127 *Statistical analysis*

128 Descriptive statistics were utilized to summarize the demographic characteristics of the  
129 cohort and significant study outcome variables. Frequency and composition ratio were used for  
130 categorical variables, Chi-square test and Fisher's exact test were used for comparing categorical  
131 variables. Multivariate logistic regression was used to calculate odds ratios and 95% confidence  
132 interval.

133 Demographic characteristics consisted of variables including gender, age groups (< 20  
134 years old, 20-40 years old, 40-60 years old and  $\geq 60$  years old), travel history(domestic or  
135 international), type (symptomatic or asymptomatic) and antibody results (positive or negative).  
136 We considered the antibody results as outcome, and it was divided into two groups (positive or  
137 negative), previous studies have found that gender and age were related to the results of the  
138 antibody[15]. Frequency and composition ratio were used to describe the total number of specific  
139 antibodies of different durations. The seroprevalence changes and positive rates of specific  
140 antibodies IgM and IgG over time were plotted. All analyses were performed by Stata 16.0  
141 software, the p-value less than 0.05 in this paper was considered statistically significant.

## 142 **Results**

### 143 *Demographic and Clinical Characteristics*

144 By November 23, 2020, A total of 177 participants (83 men; 94 women) were recruited.  
145 The median of age was 47 years (IQR = 33-57 years), asymptomatic cases(35 years) are younger  
146 than symptomatic(47 years). The types of cases were statistically different among different age

147 groups( $\chi^2= 14.0671$  ,  $P=0.003$ ).The descriptive analysis of 177 convalescents with SARS-CoV-  
148 2 infections were included (Table 1). For serology results, 152 were positive and 25 were  
149 negative. Only two subjects had international travel history.

### 150 *Specific Antibodies IgM and IgG Levels*

151 The levels of different antibodies in 177 patients infected SARS-CoV-2 were further  
152 described (Table 2). As time went by, largely of patients tended to IgG positive and IgM  
153 negative. The proportion of IgM positive in infected women was significantly lower than men,  
154 but the proportion of IgG positive was similar between different genders. People who aged  $\geq 60$   
155 years have higher IgG (94.74%)seroprevalence than IgM(10.53%), IgG positive percentage of  
156 different age groups was statistically difference( $\chi^2= 10.8514$  ,  $P=0.013$ ). Asymtomatic was  
157 lower than symptomatic for both IgG and IgM to SARS-CoV-2 seroprevalence.

### 158 *Multivariate Logistic Regression Analysis of Positive Antibody for IgM*

159 The occurrence of positive IgM antibody was taken as the dependent variable, gender and  
160 type were considered as the independent variables (Table 3), female and symptomatic cases as  
161 the reference group respectively. Different age groups were dummy variables. The age group  
162 younger than 20 years was the reference group. Previous studies have found that gender and age  
163 were related to the outcome levels of antibodies[16]. Multivariate logistic regression analysis  
164 showed that age and type of infection were not related to IgM antibody results. However, after  
165 adjustment for infected type and age, men had more than twice the odds of having IgM antibody  
166 positive compared with women (OR=2.419, 95% CI:[1.232, 4.751]).

### 167 *Multivariate Logistic Regression Analysis of Positive Antibody for IgG*



168 The antibody level of IgG antibody(positive or negative) was taken as the dependent  
169 variable, gender and type of infected person as the independent variables (Table 4), female and  
170 symptomatic cases were taken as the reference group. Different age groups were dummy  
171 variables. The age group younger than 20 years was the control group. While we excluded travel  
172 history due to its improper composition ratio. Multivariate logistic regression analysis showed  
173 that gender and type of infection were not related to IgG positive result. Participants without  
174 symptoms were nearly 0.5 times more likely to be seropositive than those with symptoms  
175 (OR=0.455, 95% CI: [0.220, 0.940]). People aged 60 years and older were nearly 3 times IgG  
176 seropositive than those who aged less than 20 years(OR=2.986, 95% CI: [1.058, 8.432]).

### 177 *The Duration of IgM and IgG*

178 Analysis of the 363 serological samples showed that the positive rate of IgG was higher  
179 than IgM, and the immune response persistence of IgG was longer than that of IgM antibody,  
180 which was consistent with the current research[17]. The median duration of IgM and IgG  
181 antibodies was 7 months. We observed duration of both antibodies persisted more than 10  
182 months. It suggested that there may be a long-term immune response after infection with SARS-  
183 CoV-2[18]. In order to comprehend the dynamics of antibody response, we took the occurrence  
184 of negative antibody as failure, and depicted the survival curve of differential antibodies. As  
185 shown in Figure 1, IgM antibody positive rates declined gradually over time after natural  
186 infection with SARS-CoV-2. Asymptomatic cases were easier turn out to negative. IgG antibody  
187 prevalence declined gradually after the sixth month(Figure 2), with duration last more than 10  
188 months. The total positive rate of symptomatic is higher than that of asymptomatic. As well as  
189 the long-term duration. The disappearance time of the two specific antibodies still needs further  
190 observation.

191 **Discussion**

192 Our study contributes more essential information for convalescents about the durability  
193 and stability of antibody response to SARS-CoV-2. Human immune response is usually  
194 measured in the blood, and IgG and IgM antibodies are thought as immune memory markers[19].  
195 We analysed the serological outcomes from 177 convalescents of COVID-19 and risk factors.  
196 After adjustment for infected type and age, men had more than twice the odds of having IgM  
197 antibody positive compared with women (OR=2.419, 95% CI:[1.232, 4.751]). Participants  
198 without symptoms were nearly 0.5 times IgG seropositive than those with symptoms (OR=0.455,  
199 95% CI: [0.220, 0.940]). Among different age groups between symptomatic cases and  
200 asymptomatic cases with statistical difference( $\chi^2= 14.0671$  ,  $P=0.003$ ). People aged  $\geq 60$  were  
201 nearly 3 times IgG seropositive than those who aged  $< 20$  years (OR=2.986, 95% CI: [1.058,  
202 8.432]). Both IgM and IgG seroprevalence declined gradually over time after natural infection  
203 with SARS-CoV-2. We also observed seroprevalence of convalescents can persist more than 10  
204 months, the disappearance still needs further observation.

205 Both IgM and IgG seroprevalence declined gradually over time after natural infection  
206 with SARS-CoV-2, with seropositive antibodies lasted more than 10 months. It was  
207 demonstrated that response wanes over time of convalescence rather than the sake of repeated  
208 donations[20]. Asymptomatic cases were easier turn out to negative. The total positive rate of  
209 IgG antibody is higher than that of IgM antibody. The seroprevalence of IgM in infected men  
210 was higher than women. Gender differences may affect SARS-CoV-2 immune response  
211 outcome[21]. When considering subgroups by gender, women are more likely have higher  
212 frequency than in men. After analysis of 363 serological samples collected, it was concluded that

213 the positive rate of IgG was significantly higher than that of IgM, and the immune response  
214 persistence of IgG was longer than IgM. Meanwhile, we observed duration of specific antibody  
215 was last more than 10 months from our data. Previous study reported was 8 months[14].

216 Ideally, this study should be based on continuous detection at time points, but in reality it  
217 is difficult to carry out continuous systematic sample collection, and not all patients have  
218 continuous observation data, which limits the continuous observation of individual antibody  
219 response reports. Our data do not yet know whether our individuals sustain low and stable levels  
220 after an initial drop in antibody levels, and the inactivation time of specific antibodies generated  
221 by natural infection with SARS-CoV-2, which requires further tracking and testing.

222 Future studies will require large sample sizes of long-term, continuous data on specific  
223 immune memory for SARS-CoV-2 to assess its association with protection. They can be  
224 conducted with long-term follow-up and detection to investigate factors strongly related to  
225 serological levels and antibody dynamics over time, provided deep insight into the immune  
226 response to SARS-CoV-2 of convalescents and better guide the development of vaccines and  
227 therapeutics.

## 228 **Author contributions**

229 CL and LJZ consulted the literature, analyzed the data, wrote the programs, and was a  
230 major contributor in writing the manuscript. XPW, HY, TJX and CKX wrote part of the  
231 manuscript. MP, CX, HPY, XWC, XYS and XBD collected the data. HWP, TH, HL, DX and  
232 WLX detected serum samples, ZP and ZDZ commented on the content of the article. YZ  
233 collected part of the data. LJ and XW made constructive comments on the manuscript. TZ  
234 contributed significantly to analysis and manuscript preparation.

## 235 **Acknowledgments**

236           The authors thank all the colleagues participating in the Sichuan Field Epidemiology  
237 Training Program and Standardized Training of Public Health Physicians in Sichuan Province  
238 for their contributions to data collection and manuscript review.

239 **Financial support**

240           This work was supported by the National Natural Science Foundation of China (grant  
241 numbers 82041033, 81602935), Sichuan Science and Technology Program (grant numbers  
242 2020YFS0015, 2020YFS0091, 2021YFS0001), Health Commission of Sichuan Province (grant  
243 number 20PJ092, 20ZDCX001), Chongqing Science and Technology Program (grant number  
244 cstc2020jscxcylhX0003), and Humanities and Social Sciences Program of Sichuan University  
245 (grant number 2018hhf-26). The funding body did not participate in the design, collection,  
246 analysis, interpretation and writing of this study.

247 **Conflicts of interest**

248           The authors: No reported conflicts of interest.

249

250 **References**

- 251 [1] Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19  
252 in patients discharged from hospital: a cohort study. *The Lancet*. 2021;397:220-32.  
253 [https://doi.org/10.1016/s0140-6736\(20\)32656-8](https://doi.org/10.1016/s0140-6736(20)32656-8)
- 254 [2] Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, et al. Antibody Detection and Dynamic  
255 Characteristics in Patients with COVID-19. *Clin Infect Dis*. 2020.  
256 <https://doi.org/10.1093/cid/ciaa461>
- 257 [3] Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and clinical application of a  
258 rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. *J Med Virol*.  
259 2020;92:1518-24. <https://doi.org/10.1002/jmv.25727>
- 260 [4] De Marinis Y, Sunnerhagen T, Bompada P, Blackberg A, Yang R, Svensson J, et al. Serology  
261 assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG  
262 antibody test. *Infect Ecol Epidemiol*. 2020;10:1821513.  
263 <https://doi.org/10.1080/20008686.2020.1821513>
- 264 [5] Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, et al. Defining the  
265 features and duration of antibody responses to SARS-CoV-2 infection associated with disease  
266 severity and outcome. *Sci Immunol*. 2020;5. <https://doi.org/10.1126/sciimmunol.abe0240>
- 267 [6] To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, et al. COVID-19 re-infection by a  
268 phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing.  
269 *Clin Infect Dis*. 2020. <https://doi.org/10.1093/cid/ciaa1275>
- 270 [7] Chow CC, Chang JC, Gerkin RC, Vattikuti S. Global prediction of unreported SARS-CoV2  
271 infection from observed COVID-19 cases. *medRxiv : the preprint server for health sciences*.  
272 2020. <https://doi.org/10.1101/2020.04.29.20083485>

- 273 [8] Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-  
274 CoV-2 in patients with COVID-19. *Nature medicine*. 2020;26:845-8.  
275 <https://doi.org/10.1038/s41591-020-0897-1>
- 276 [9] Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies  
277 in patients with coronavirus disease 2019. *Clinical & Translational Immunology*. 2020;9.  
278 <https://doi.org/10.1002/cti2.1136>
- 279 [10] Li G, Chen X, Xu A. Profile of specific antibodies to the SARS-associated coronavirus. *N*  
280 *Engl J Med*. 2003;349:508-9. <https://doi.org/10.1056/nejm200307313490520>
- 281 [11] Wu LP, Wang NC, Chang YH, Tian XY, Na DY, Zhang LY, et al. Duration of antibody  
282 responses after severe acute respiratory syndrome. *Emerging infectious diseases*. 2007;13:1562-4.  
283 <https://doi.org/10.3201/eid1310.070576>
- 284 [12] Zhou W, Xu X, Chang Z, Wang H, Zhong X, Tong X, et al. The dynamic changes of serum  
285 IgM and IgG against SARS-CoV-2 in patients with COVID-19. *J Med Virol*. 2021;93:924-33.  
286 <https://doi.org/10.1002/jmv.26353>
- 287 [13] Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and  
288 applications to phase 3 vaccine candidates. *The Lancet*. 2020;396:1595-606.  
289 [https://doi.org/10.1016/s0140-6736\(20\)32137-1](https://doi.org/10.1016/s0140-6736(20)32137-1)
- 290 [14] Choe PG, Kim KH, Kang CK, Suh HJ, Kang E, Lee SY, et al. Antibody Responses 8 Months  
291 after Asymptomatic or Mild SARS-CoV-2 Infection. *Emerging infectious diseases*. 2020;27.  
292 <https://doi.org/10.3201/eid2703.204543>
- 293 [15] Guo X, Zeng L, Huang Z, He Y, Zhang Z, Zhong Z. Longer Duration of SARS-CoV-2  
294 Infection in a Case of Mild COVID-19 With Weak Production of the Specific IgM and IgG  
295 Antibodies. *Front Immunol*. 2020;11:1936. <https://doi.org/10.3389/fimmu.2020.01936>

- 296 [16] Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-  
297 2 antibody: An up-to-date review. *Int J Infect Dis.* 2020.  
298 <https://doi.org/10.1016/j.ijid.2020.10.011>
- 299 [17] Wang B, Wang L, Kong X, Geng J, Xiao D, Ma C, et al. Long-term coexistence of SARS-  
300 CoV-2 with antibody response in COVID-19 patients. *J Med Virol.* 2020;92:1684-9.  
301 <https://doi.org/10.1002/jmv.25946>
- 302 [18] Bruni M, Cecatiello V, Diaz-Basabe A, Lattanzi G, Mileti E, Monzani S, et al. Persistence of  
303 Anti-SARS-CoV-2 Antibodies in Non-Hospitalized COVID-19 Convalescent Health Care  
304 Workers. *Journal of Clinical Medicine.* 2020;9. <https://doi.org/10.3390/jcm9103188>
- 305 [19] Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell.* 2021.  
306 <https://doi.org/10.1016/j.cell.2021.01.007>
- 307 [20] Perreault J, Tremblay T, Fournier MJ, Drouin M, Beaudoin-Bussièrès G, Prévost J, et al.  
308 Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4  
309 months after symptom onset. *Blood.* 2020;136:2588-91.  
310 <https://doi.org/10.1182/blood.2020008367>
- 311 [21] Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in  
312 immune responses that underlie COVID-19 disease outcomes. *Nature.* 2020;588:315-20.  
313 <https://doi.org/10.1038/s41586-020-2700-3>  
314  
315

316 **Table 1. Demographic and Clinical Characteristics**

	Total	asymptomatic	symptomatic	<i>P</i>
	No	No. (%)	No. (%)	
	177	21(11.86)	156(88.14)	
<b>Gender</b>				
Female	94	8(8.51)	86(91.49)	0.142
Male	83	13(15.66)	70(84.34)	
<b>Age,median(IQR)</b>				
< 20 years	15	6(40.00)	9(60.00)	0.003
20-40 years	53	6(11.32)	47(88.68)	
40-60 years	71	4(5.63)	67(94.37)	
≥60 years	38	5(13.16)	33(86.84)	
<b>Serology assessment</b>				
Negative	25	5(20.00)	20(80.00)	0.185
Positive	152	16(10.53)	136(89.47)	
<b>Travel history</b>				
Domestic	2	1(50.00)	1(50.00)	0.224
International	175	20(11.43)	155(88.57)	

317 Values are medians (IQR) or n (%). Groups were compared using Chi-square test or Fisher's  
 318 exact test.

319 Abbreviations: IQR, inter-quartile range

320



321 Table 2. Specific Antibodies IgM and IgG Levels

	Total	IgM No. (%)		<i>P</i>	IgG No. (%)		<i>P</i>
		negative	positive		negative	positive	
	177	154(87.01)	23(12.99)		26(14.69)	151(85.31)	
<b>Gender</b>							
Female	94	86(91.49)	8(8.51)	0.059	11(11.7)	83(88.3)	0.232
Male	83	68(81.93)	15(18.07)		15(18.07)	68(81.93)	
<b>Age</b>							
< 20 years	15	14(93.33)	1(6.67)	0.376	5(33.33)	10(66.67)	0.013
20-40 years	53	48(90.57)	5(9.43)		12(22.64)	41(77.36)	
40-60 years	71	58(81.69)	13(18.31)		7(9.86)	64 (90.14)	
≥60 years	38	34(89.47)	4(10.53)		2(5.26)	36(94.74)	
<b>Type</b>							
Asymptomatic	21	20(95.24)	1(4.76)	0.318	5(23.81)	16(76.19)	0.209
Symptomatic	156	134(85.9)	22(14.1)		21(13.46)	135(86.54)	
<b>Travel history</b>							
Domestic	2	1(50.00)	1(50.00)	0.244	0(0.00)	2 (100.00)	1.000
International	175	153(87.43)	22(12.57)		26(14.86)	140 (85.14)	

322 Values are n (%). Groups were compared using Chi-square test or Fisher's exact test.

323 Abbreviations: IgG, immunoglobulin G; IgM, immunoglobulin M

324

325 Table 3. Multivariate Logistic Regression Analysis of Positive Antibody for IgM

	$\beta$	OR	<i>P</i>	95% CI.	
				lower	upper
Gender	0.883	2.419	0.010	1.232	4.751
Type	-1.074	0.342	0.165	0.075	1.557
Age(<20 years)					
Age(20-40 years)	0.676	1.967	0.544	0.221	17.470
Age(40-60years)	1.336	3.806	0.219	0.452	32.060
Age( $\geq$ 60 years)	0.713	2.040	0.525	0.227	18.320

326 Abbreviation: OR: odds ratio; CI: confidence interval ;

327


328 Table 4. Multivariate Logistic Regression Analysis of Positive Antibody for IgG

	$\beta$	OR	<i>P</i>	95% CI.	
				lower	upper
Gender	0.060	1.062	0.820	0.632	1.786
Type	-0.788	0.455	0.034	0.220	0.940
Age(<20 years)					
Age(20-40 years)	0.133	1.143	0.788	0.431	3.028
Age(40-60years)	0.653	1.921	0.194	0.717	5.153
Age( $\geq$ 60 years)	1.094	2.986	0.039	1.058	8.432

329 Abbreviation: OR: odds ratio; CI: confidence interval


330

331 **Figure 1. Duration of IgM antibodies among asymptomatic and symptomatic**



332

333 **Figure 2. Duration of IgG antibodies among asymptomatic and symptomatic**



334